Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma

被引：16

作者：

Bartholomew, Joy ^{[1
]}

Washington, Tanea ^{[2
]}

Bergeron, Sharon ^{[4
]}

Nielson, Danelle ^{[5
]}

Saggio, Jennifer ^{[6
]}

Quirk, Lindsay ^{[3
]}

机构：

[1] Childrens Mercy Hosp Kansas City, Oncol, Kansas City, MO USA

[2] Childrens Hosp Los Angeles, Inpatient Pediat Oncol Serv, Los Angeles, CA 90027 USA

[3] Childrens Hosp Los Angeles, Oncol Serv, Los Angeles, CA 90027 USA

[4] Childrens Hosp Orange Cty, Los Angeles, CA USA

[5] Primary Childrens Med Ctr, Stem Cell Transplant, Salt Lake City, UT USA

[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

来源：

JOURNAL OF PEDIATRIC ONCOLOGY NURSING | 2017年 / 34卷 / 01期

关键词：

immunotherapy; infusion management; patient safety; MONOCLONAL-ANTIBODIES; NEURO-BLASTOMA; INTERLEUKIN-2; GANGLIOSIDE; CHILDREN; ACID;

D O I：

10.1177/1043454216659448

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.

引用

页码：5 / 12

页数：8

共 19 条

[1]

[Anonymous], 1975, Cancer Statistics Review

[2]

Baluna RG., 2007, CYTOKINES HUMAN HLTH, P205, DOI [10.1007/978-1-59745-350-9_11, DOI 10.1007/978-1-59745-350-9_11]

[3] Neuroblastoma: Biological insights into a clinical enigma [J].

Brodeur, GM .

NATURE REVIEWS CANCER, 2003, 3 (03) :203-216

[4]

Chameides Leon., 2011, Pediatric Advanced Life Support Provider Manual

[5] Immunotoxicity of monoclonal antibodies [J].

Descotes, Jacques .

MABS, 2009, 1 (02) :104-111

[6] Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug [J].

Gillin, S ;

Sorkin, LS .

ANESTHESIA AND ANALGESIA, 1998, 86 (01) :111-116

[7] Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma [J].

Kremens, B ;

Hero, B ;

Esser, J ;

Weinel, P ;

Filger-Brillinger, J ;

Fleischhack, G ;

Graf, N ;

Grüttner, HP ;

Niemeyer, C ;

Schulz, A ;

Wickmann, L ;

Berthold, F .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (02) :107-110

[8] Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study [J].

Matthay, Katherine K. ;

Reynolds, C. Patrick ;

Seeger, Robert C. ;

Shimada, Hiroyuki ;

Adkins, E. Stanton ;

Haas-Kogan, Daphne ;

Gerbing, Robert B. ;

London, Wendy B. ;

Villablanca, Judith G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1007-1013

[9]

Ozkaynak F., 2014, AM SOC CLIN ONC ANN

[10] Targeted Immunotherapy for High-Risk Neuroblastoma-The Role of Monoclonal Antibodies [J].

Parsons, Kerry ;

Bernhardt, Brooke ;

Strickland, Brandy .

ANNALS OF PHARMACOTHERAPY, 2013, 47 (02) :210-218

← 1 2 →